Taysha gene therapies to release third quarter 2025 financial results and host conference call and webcast on november 4

Dallas, oct. 28, 2025 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha) (taysha or the company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (aav)-based gene therapies for severe monogenic diseases of the central nervous system (cns), today announced that it will report its financial results for the third quarter ended september 30, 2025, and host a corporate update conference call and webcast on tuesday, november 4, 2025, at 8:30 am eastern time.
TSHA Ratings Summary
TSHA Quant Ranking